Skip to main content
ATOSSA THERAPEUTICS, INC. logo

ATOSSA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · ATOS ISIN · US04962H5063 US Manufacturing
Open in API
Filings indexed 622 across all filing types
Latest filing 2020-03-26 Annual Report
Country US United States of America
Listing US ATOS

About ATOSSA THERAPEUTICS, INC.

https://atossatherapeutics.com/

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative medicines for areas of significant unmet medical need, with a primary focus on oncology. The company is dedicated to addressing the full continuum of breast cancer care. Its lead program is centered on (Z)-endoxifen, a proprietary and potent selective estrogen receptor modulator (SERM). Atossa is advancing (Z)-endoxifen through clinical development for multiple breast cancer indications, including metastatic disease, aiming to provide a therapeutic with a potentially improved efficacy and tolerability profile.

Recent filings

Filing Released Lang Actions
FORM 10-K
Annual Report FY 2019
2020-03-26 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 26, 2020, reporting the results of operations and financial condition for the year ended December 31, 2019. It specifically states that the company issued a press release announcing year-end financial results and a company update, and the press release is attached as an exhibit. The document itself is short (3758 characters) and primarily serves to announce the release of financial results via a press release rather than containing detailed financial statements or analysis. According to the 'Menu vs Meal' rule, such a document is an announcement of a report (press release) rather than the report itself. Therefore, the appropriate classification is Earnings Release (ER), as it is the initial announcement of quarterly/periodical financial results (key highlights only).
2020-03-26 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 7, 2020. It reports the entry into a material definitive agreement, specifically an equity distribution agreement for an 'at-the-market' offering of common shares. The document includes details about the agreement, commission, and references to exhibits such as the agreement text and legal opinions. There are no financial statements or comprehensive financial data presented, nor is this a full annual or quarterly report. The content is an update on a capital raising activity, which fits the category of Capital/Financing Update filings. The document length is 4514 characters, which is consistent with a typical 8-K filing for such an event. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2020-02-07 English
FORM 424B3
Capital/Financing Update Classification · 95% confidence The document is a Form 424B3 prospectus supplement filed pursuant to Rule 424(b)(3) under the Securities Act of 1933. It relates to an equity distribution agreement for the sale of common stock, describing terms of the offering, use of proceeds, risk factors, and plan of distribution. The document is a detailed offering prospectus supplement and accompanying prospectus, which are typical for capital raising activities. It is not a financial report, earnings release, or management discussion, nor is it a regulatory filing or announcement of a report. The content clearly indicates it is a capital/financing update related to a stock offering. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2020-02-07 English
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated January 6, 2020. It announces a corporate name change from 'Atossa Genetics Inc.' to 'Atossa Therapeutics, Inc.' and amendments to the company's bylaws to reflect this change. There are no financial statements or detailed financial data included. The document is primarily an announcement of corporate governance changes, specifically amendments to articles of incorporation and bylaws. This fits best under the category of Board/Management Information (MANG), which includes announcements of changes in the company's board or senior management or related corporate governance changes. The document is not an annual or quarterly report, audit report, or earnings release, nor is it a proxy or voting result announcement. It is also not a regulatory filing of miscellaneous nature since it specifically relates to governance changes. Therefore, the classification is MANG with high confidence.
2020-01-07 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The key content is in Item 2.02, which states the company issued a press release announcing quarterly financial results for the period ended September 30, 2019. The document itself does not contain detailed financial statements or substantive financial data but references an attached press release (Exhibit 99.1). The document length is 3768 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, if a document is short and primarily announces or attaches a report (like a press release of earnings), it should be classified as an Earnings Release (ER) if it contains key highlights only. Since this is a press release announcing quarterly financial results, it fits the Earnings Release category rather than a full Interim/Quarterly Report (IR). Therefore, the correct classification is ER with high confidence.
2019-11-13 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.